By proceeding, you agree to our Terms of Use and Privacy Policy.
Deyaa Adib, MD is the CMO for Triumvira Immunologics and brings over 24 years of medical oncology experience in the biotech and pharmaceutical industries, including 7 successful registrations across various hematologic as well as solid tumor maladies. Most recently, he was the founder of MariCel Clinical Consulting , LLC, offering strategic services to the biotech industry.Dr Adib held multiple seats as a scientific advisory board member at several biotech companies including Imbrium Therapeutics, a Perdue Pharma subsidiary, and a strategic consultant for advanced cell therapy programs through 1st IND at Bellicum Pharmaceuticals for the BPX-601: GoCAR-T® currently in Phase I/II clinical trials for solid tumors and at KSQ for eTIL™ autologous cell therapy candidates, KSQ-001. Past leadership roles include acting Chief Medical Officer at Rain Therapeutics advancing the clinical programs and designing clinical strategy to build the oncology portfolio leading to a successful IPO. In addition, Dr Adib was Vice President, Late-Stage Development at Blueprint Medicines and Global Therapeutics Head for Solid Tumors at Baxalta, Inc, advancing the development and licensing a nano liposomal irinotecan later approved for pancreatic cancer & leading the clinical evaluation for acquiring Oncaspar from Sigma-Tau Pharmaceuticals (Leadiant Biosciences, Inc) approved in ALL. He also led the licensing of a CD19 target CAR-T from Precision Biosciences and a PDL1, LAG3, TIM3 check point inhibitor targets from Symphogen a subsidiary of Servier. He was head of hematologic Malignancies at ARIAD leading the global clinical programs for ponatinib in CML later acquired by Takeda.Dr Adib has also held multiple oncology clinical development leadership positions at Aventis, Sanofi and Astellas Pharma where he advanced the development of docetaxel in prostate cancer, breast cancer and gastric cancer, enzalutamide in prostate cancer, quizartinib in AML, erlotinib in NSCLC and pancreatic cancer.
Talks About #ClinicalDevelopment #Oncology #PharmaceuticalIndustry
Preferred Locations #UnitedStates
The 10th annual Chief Medical Officer Summit 360° attracts the largest gathering of physicians in biotech to address the unique challenges associated with directing and managing R&D functions with limited resources, while raising capital and strategizing for appropriate exits.
Over the past 10 years, CHI's Immuno-Oncology Summit has become the leading annual meeting focusing on the latest applied research, providing comprehensive and in-depth coverage across all modalities and stages in the pipeline.
The World Oncology Cell Therapy Congress is the only annual meeting bringing together drug developers, investors, solution providers and clinicians whose purpose is to deliver safe and effective adoptive cell therapy products to clinical implementation.
